1,5-dimethyl-2-(4-methylbenzoyl)pyrrole | 62128-36-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,5-dimethyl-2-(4-methylbenzoyl)pyrrole
• 英文别名: p-tolyl 1,5-dimethylpyrrol-2-yl ketone；1,2-dimethyl-5-p-toluoylpyrrole；(1,5-Dimethyl-1H-pyrrol-2-yl)(4-methylphenyl)methanone；(1,5-dimethylpyrrol-2-yl)-(4-methylphenyl)methanone
• CAS: 62128-36-3
• 化学式: C₁₄H₁₅NO
• 分子量: 213.279
• InChiKey: WIMNBZPDJQBWEA-UHFFFAOYSA-N

物化性质

• 熔点：
  80-82 °C(Solv: hexane (110-54-3))
• 沸点：
  370.2±30.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,5-dimethyl-2-(4-methylbenzoyl)pyrrole 以 对甲苯磺酸 为溶剂， 生成 1,2-Dimethyl-4-p-toluylpyrrol
  参考文献：
  名称：

  Preparation of .beta.-acyl pyrroles

  摘要：

  一种将α-酰基吡咯重排为β-酰基吡咯的过程，包括将前者与过量的强、无水、非氧化性酸反应，最好在加热条件下进行。

  公开号：

  US04002643A1
• 作为产物：
  描述：

  托麦汀 以 水 为溶剂， 生成 1,5-dimethyl-2-(4-methylbenzoyl)pyrrole
  参考文献：
  名称：

  Tolmetin 的激光闪光光解：以三重碳负离子为关键中间体的光绝热脱羧反应

  摘要：

  摘要——托美汀 (TM), 5-(对甲苯甲酰基)-1-甲基-2-吡咯乙酸, 一种属于非甾体抗炎类的药物, 在水溶液中使用纳秒激光闪光进行了瞬态光化学研究。光解技术。TM 的光反应性的特征在于涉及作为光脱羧关键中间体的三线态碳负离子的绝热途径。一个短命的三联体被提议作为这种瞬态物种的前体。还确定了涉及光电离的激光光分解的次要通道。后一种光处理主要通过双光子机制发生。

  DOI：

  10.1111/j.1751-1097.1999.tb03270.x

文献信息

• Copper(II), in the parts per million range, modulates photochemical and photosensitizing properties of tolmetin via electron transfer with a triplet carbanion
  作者：S. Sortino、G. De Guidi、L. L. Costanzo、S. Sortino、J. C. Scaiano

  DOI：10.1039/a906349h

  日期：——

  Copper(II), at very low levels of concentration, modulates the distribution of tolmetin stable photoproducts as well as inhibits the DNA cleavage photoinduced by the drug, via a highly efficient electron transfer process with the main transient species generated in the tolmetin photolysis.

  在极低浓度下，铜（II）通过与托美汀光解过程中产生的主要瞬时物种进行高效电子转移，调节托美汀稳定光产物的分布，并抑制该药物光诱导的 DNA 裂解。
• Photolysis of NSAIDs. Part 3: Structural elucidation of photoproducts of tolmetin in methanol
  作者：Ming-Thau Sheu、Jender Wu、Chih-Jui Chen、Su-Hui Chao、An-Bang Wu

  DOI：10.1016/j.tetlet.2004.08.177

  日期：2004.10

  in methanol was photo-irradiated with a Hanovia 200 W high-pressure quartz Hg lamp for four days. In total, eight photoproducts were observed from the HPLC chromatogram. Three major photoproducts were separated, and their structures were elucidated by spectroscopic methods. The structures of all photoproducts were further determined by LC–ESI-MS. A reaction scheme of tolmetin was proposed.

  用Hanovia 200 W高压石英汞灯对甲醇中的10 mM托美汀样品进行光辐照四天。从HPLC色谱图中总共观察到八种光产物。分离了三种主要的光产物，并通过光谱法阐明了它们的结构。LC-ESI-MS进一步确定了所有光产物的结构。提出了托美汀的反应方案。
• ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS
  申请人：Cannizzaro Carina

  公开号：US20090247488A1

  公开（公告）日：2009-10-01

  The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗炎化合物、含有这种化合物的组合物、包括给药这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093708A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型的亚硝基化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，以及包含至少一种亚硝基化NSAID的新型组合物，可选地包含至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性松弛因子水平或是一氧化氮合酶底物的化合物，以及/或至少一种治疗剂。该发明还提供包含至少一种亚硝基化NSAID和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供包含至少一种亚硝基化NSAID，可选地包括至少一种一氧化氮供体和/或至少一种治疗剂的新型套件。该发明还提供用于治疗炎症、疼痛和发热的方法；用于治疗胃肠道疾病的方法；用于促进伤口愈合的方法；用于治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；用于治疗炎症性疾病状态和/或疾病的方法；以及用于治疗和/或预防眼科疾病和/或疾病的方法。
• MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC
  申请人：ANDERSSON Johan

  公开号：US20090170934A1

  公开（公告）日：2009-07-02

  The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl 2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.

  本发明涉及一种使用磺化中间体制备NO供体化合物的新工艺。该发明涉及其中制备的适用于NO供体化合物大规模生产的新中间体。本发明还涉及使用新中间体制造药用活性NO供体化合物。此外，本发明还涉及NO供体NSAIDs的实质晶体形式，特别是2-[2-(硝氧基)乙氧基]乙基2-[(2,6-二氯苯基)氨基]苯基}乙酸酯的制备，以及含有该晶体形式的制药配方和在制备药物时使用该晶体形式的用途。